Hormone Therapy Linked to More Frequent, Longer Migraines in Postmenopausal Women
A meta-analysis of five studies and nearly 24,000 women links hormone therapy to more frequent, longer migraines, though severity and painkiller use did not differ.
Résumé
Migraine and menopausal hormone therapy are the focus of a new systematic review and meta-analysis to be presented at the 2026 Menopause Society meeting. Researchers pooled five studies covering nearly 24,000 postmenopausal women, with an average migraine incidence of about 19%. Women using hormone therapy had more frequent migraine attacks and longer-lasting episodes. However, they did not differ in migraine severity scores or in how many analgesics they used each month. The authors call for further clinical trials to clarify the underlying physiology. The Menopause Society's medical director cautions against reading the result as cause and effect. Women with migraine may be more likely to seek treatment for menopause symptoms, so the findings may reflect differences between women who choose hormone therapy and those who do not. She notes that hormone therapy remains the most effective treatment for bothersome hot flashes and night sweats, and can be used safely in many women with migraine. Decisions should be individualized.
Résumé détaillé
Migraine affects roughly 10% to 29% of women during the menopause transition, and attacks often worsen and become more frequent in perimenopause because estrogen levels fall unpredictably. Hormone therapy is the most effective treatment for bothersome vasomotor symptoms such as hot flashes, but because estrogen fluctuations can influence migraine, clinicians and patients want to know how treatment affects headache outcomes after menopause.
To address this, researchers led by Dr. Flavia Fairbanks Ruano of the University of Miami Miller School of Medicine conducted a systematic review and meta-analysis. They pooled five studies including nearly 24,000 postmenopausal women and examined migraine incidence, severity, frequency, duration and analgesic use, regardless of how the hormones were administered. The pooled mean migraine incidence was 18.94%.
Hormone therapy use was associated with more frequent migraine attacks and longer-lasting episodes. Yet there were no significant differences in the number of analgesics used per month or in migraine severity scores. In other words, the burden in terms of time spent with migraine appeared higher, but the intensity of attacks and the need for pain medication did not.
The finding is an association, not proof that hormones cause more migraines. Dr. Stephanie Faubion of The Menopause Society noted that women with migraine may be more likely to seek menopause treatment, so users and non-users may differ at baseline. This reverse-causation or confounding possibility is central to interpreting the result.
Practically, the study does not argue against hormone therapy. Faubion emphasizes that it remains the most effective option for vasomotor symptoms and can be used safely in many women with migraine. Women who have migraine and are considering therapy should discuss options, including dose and route, with a clinician and track attack frequency and duration. The authors say more clinical trials are needed to understand the mechanisms and guide treatment. The work is a conference presentation based on pooled observational data, so details should be checked once the full paper is published.
Principales conclusions
- Meta-analysis of five studies covering nearly 24,000 postmenopausal women examined hormone therapy and migraine outcomes.
- Hormone therapy use was associated with more frequent migraine attacks and longer-lasting episodes.
- Migraine severity scores and monthly analgesic use did not differ significantly between users and non-users.
- Pooled mean migraine incidence in the analyzed women was 18.94%.
- Experts caution that confounding may explain the link; hormone therapy can be safe for many women with migraine.
Méthodologie
This is a press release on a conference presentation of a systematic review and meta-analysis. The source, The Menopause Society, is a credible professional organization, but the work has not been peer-reviewed in full. The evidence rests on five pooled studies, likely observational.
Limites de l'étude
The association may reflect confounding, since women with migraine may be more likely to seek hormone therapy. Details such as study designs, dosages, routes and effect sizes are not reported, and only five studies were pooled. Verify against the full published paper and await clinical trials.
Ce résumé vous a plu ?
Recevez les dernières recherches sur la longévité dans votre boîte de réception chaque semaine.
Saisissez votre e-mail pour vous abonner :
